Kinase-independent signaling by PIM1 promotes drug resistance by increasing mitophagy and reducing oxidative stress
Cancer Letters · 2026-08 · 654 · 218611
DOI: 10.1016/j.canlet.2026.218611 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Letters, 2026-08. Verfasst von Hope Liou und 9 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Biology Graduate Program, University of Arizona, Tucson, AZ, USA. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins c-pim-1, Mitophagy, Drug Resistance, Neoplasm, Oxidative Stress. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: US Department of Defense, University of Arizona, National Institutes of Health National Cancer Institute.
Abstract (Originalsprache)
PIM kinases are overexpressed in castration resistant prostate cancer (CRPC) and many small molecule PIM kinase inhibitors (smPIM inhibitors) have been designed to block the catalytic activity of PIM. However, smPIM inhibitors have shown limited efficacy in solid tumors. Notably, all these inhibitors share the common property that they increase total PIM protein levels, which limits their efficacy because PIM1 has kinase-independent pro-survival effects. Here, we identify high mobility box group 1 (HMGB1) as a novel PIM1 binding partner. Stabilization of PIM1 by smPIM inhibitors increases the cytosolic accumulation of HMGB1, which leads to activation of mitophagy and suppresses oxidative-stress induced cell death. Knockdown of PIM1/2/3 and/or HMGB1 sensitizes cancer cells to smPIM inhibitors. In contrast, treatment with a PIM PROTAC (PIMTAC) that we developed overcomes the kinase-independent pro-survival effects of PIM1 and is more effective than smPIM inhibitors in vitro and in vivo. These results uncover a mechanism of resistance that has limited the success of smPIM inhibitors and provides compelling evidence that targeted degradation of PIM is needed to realize its potential as an anti-cancer target.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cancer Biology Graduate Program, University of Arizona, Tucson, AZ, USA.
- Department of Biochemistry and Molecular Biology, Medical University of South Carolina, Charleston, SC, USA.
- Department of Cellular and Molecular Medicine, University of Arizona, Tucson, AZ, USA.
- Department of Medicine, Division of Endocrinology, University of Arizona, Tucson, AZ, USA.
- Department of Pharmacology and Toxicology, R. K. Coit College of Pharmacy, University of Arizona, Tucson, AZ, USA.
- Department of Biochemistry and Molecular Biology, Medical University of South Carolina, Charleston, SC, USA. Electronic address: warfeln@MUSC.edu.
Förderung
- US Department of Defense
- University of Arizona
- National Institutes of Health National Cancer Institute
Zitieren
APA
Liou, H., Chauhan, S. S., Flores, C. E., Kinkade, R., Ressel, M. R., Cress, A. E., Langlais, P. R., Sutar, Y. B., Date, A. A., & Warfel, N. A. (2026). Kinase-independent signaling by PIM1 promotes drug resistance by increasing mitophagy and reducing oxidative stress. Cancer Letters, 654, 218611. https://doi.org/10.1016/j.canlet.2026.218611
Vancouver
Liou H, Chauhan SS, Flores CE, Kinkade R, Ressel MR, Cress AE, et al. Kinase-independent signaling by PIM1 promotes drug resistance by increasing mitophagy and reducing oxidative stress. Cancer Letters. 2026;654:218611. doi:10.1016/j.canlet.2026.218611
BibTeX
@article{Liou2026,
author = {Liou, Hope and Chauhan, Shailender S and Flores, Caitlyn E and Kinkade, Rose and Ressel, Madeline R and Cress, Anne E and Langlais, Paul R and Sutar, Yogesh B and Date, Abhijit A and Warfel, Noel A},
title = {Kinase-independent signaling by PIM1 promotes drug resistance by increasing mitophagy and reducing oxidative stress},
journal = {Cancer Letters},
year = {2026},
volume = {654},
pages = {218611},
doi = {10.1016/j.canlet.2026.218611}
}
EUVIMED